The Clorox Company (CLX) Down 5.4% — Should I Accept This Outcome and Sell?
The Clorox Company (CLX) gave back meaningful ground in Monday's session, dropping 5.43% and shedding $5.20 to close at $90.60 on the NYSE. The decline adds to a troubling longer-term pattern: CLX now sits roughly 31.4% below its 52-week high of $132.03, reached on July 23, 2025—a gap that underscores how far sentiment has deteriorated over the past several months and how difficult it has been for the stock to find durable footing.
Volume was notably elevated, with approximately 3.4 million shares changing hands against the 90-day average of roughly 2.6 million. That above-average turnover on a down day is not an encouraging sign, suggesting active selling pressure rather than a quiet drift lower. The combination of heavy volume and a sharp price decline points to genuine conviction on the part of sellers in this session.
Why The Clorox Company Price is Moving Lower
Today's decline is best understood as a market re-pricing of a company still working through a layered set of operational and financial challenges. The most clearly identifiable trigger in recent weeks was a mixed first-quarter earnings report that sent the stock down approximately 9.1% in morning trading, after Clorox posted organic sales below consensus and simultaneously cut its annual forecast. Management cited weaker consumer sentiment, higher energy costs, and the financial impact of integrating the Purell maker acquisition as the primary drivers behind the more cautious outlook—a combination that left analysts and investors with little to hold on to as a near-term recovery catalyst.
The longer-running headwind is Clorox's U.S. ERP system rollout, which disrupted order fulfillment and shipments and directly weighed on reported sales figures. That operational disruption has proven stubbornly difficult to resolve cleanly, and investors are still waiting for concrete evidence that fulfillment has normalized and that volume trends are recovering. Multiple analysts have responded by cutting price targets, with at least one outright downgrade as the Street has reassessed the company's near-term growth, margin trajectory, and earnings power. Revenue growth of just 0.12% captures the magnitude of the stagnation—essentially flat top-line progress in a period when cost pressures have continued to build.
The pressure on CLX also reflects a broader reassessment of the risk profile embedded in the shares. With profit margins at 11.18% and guidance already trimmed, investors have limited cushion if execution stumbles further. The 5.18% dividend yield, while attractive on the surface, is now as much a function of a falling stock price as it is a sign of shareholder-friendly capital allocation—and for some investors, a yield at this level against a backdrop of eroding fundamentals raises questions about sustainability rather than providing genuine comfort.
What is the The Clorox Company Rating - Should I Sell?
Weiss Ratings assigns CLX a C rating. Current recommendation is Hold.
The rating reflects a company caught between pockets of genuine operational strength and a set of structural concerns that are difficult to dismiss. On the efficiency side, an ROE of 546.10% earns the Excellent Efficiency Index—a figure that, while arithmetically distorted by a deeply negative equity base rather than exceptional earnings power alone, does highlight how intensely asset-light and brand-leveraged Clorox's business model remains. Revenue growth of 0.12% and a profit margin of 11.18% together earn a Good Growth Index, indicating the company is at least generating real earnings from its sales base even as top-line expansion has essentially stalled.
The weaker side of the Weiss profile deserves careful attention. The Weak Solvency Index reflects the balance sheet strain that accompanies Clorox's leverage profile—a meaningful risk when interest costs are elevated and cash flows are being pressured by ERP-related disruption and integration spending. The Weak Total Return Index indicates that, over a meaningful measurement horizon, CLX has not rewarded investors in a way that competes favorably with alternatives in the Consumer Staples space. The Weak Volatility Index rounds out the concern, flagging that the stock has experienced meaningful price swings—a pattern fully on display today—making it a more turbulent hold than the defensive Consumer Staples label might imply.
A forward P/E of 15.54 is not demanding in isolation, but it presupposes that earnings estimates hold at current levels. Given the recent guidance cut and the unresolved operational headwinds, that assumption carries more risk than usual. The 5.18% dividend yield provides income support for patient holders, but investors relying on it to justify the position should monitor payout coverage carefully as earnings visibility remains constrained.
Within Consumer Staples sector, CLX is on equal footing with The Procter & Gamble Company (PG, C) and Kenvue Inc. (KVUE, C), while lagging behind both Colgate-Palmolive Company (CL, C+) and Church & Dwight Co., Inc. (CHD, C+). It ranks ahead of Kimberly-Clark Corporation (KMB, C-), though that distinction offers limited reassurance given the breadth of challenges CLX is currently navigating.
About The Clorox Company
The Clorox Company (CLX) is a Consumer Staples company built around a portfolio of cleaning, disinfecting, and lifestyle brands that have earned strong household recognition across generations. The company's flagship Clorox bleach and disinfecting products remain category staples in home cleaning and sanitization, with brand equity deepened further during the pandemic period. Beyond its cleaning core, Clorox owns a diversified set of consumer brands spanning food products under the Hidden Valley and KC Masterpiece labels, grilling and charcoal under Kingsford, water filtration through Brita, and personal care and wellness through brands including Burt's Bees.
Clorox operates primarily in the United States, where it holds leading or strong share positions across several of its core categories, with a more modest international footprint that provides some geographic diversification. The company's competitive advantages are rooted in brand strength, retail shelf presence, and established distribution relationships—factors that have historically supported pricing power and margin stability in a category where private-label competition is persistent. Its product portfolio is anchored in consumable, repeat-purchase categories, lending the business a degree of demand resilience across economic cycles that is characteristic of well-positioned Consumer Staples operators.
The company's recent acquisition of the Purell maker adds a premium hand sanitization and hygiene brand to its professional and consumer-facing lineup, extending its reach in the health and hygiene segment. That integration, however, is currently contributing to the near-term financial complexity that investors are working to assess, alongside the ERP transition that has weighed on operational execution. Over the longer term, Clorox's brand depth and category positions remain the foundation of its investment case, even as the near-term path to restoring earnings momentum remains less certain than it once appeared.
Investor Outlook
The Clorox Company (CLX) carries a Weiss Rating of C (Hold), reflecting a business with durable brand assets but real near-term execution risk that warrants caution rather than conviction. Investors should watch for evidence that the ERP disruption has been resolved, that organic sales trends are stabilizing, and that guidance stops getting revised downward before reassessing the risk/reward balance in the shares. See full rankings of all C-rated Consumer Staples stocks inside the Weiss Stock Screener.
--